Quality Risk Management (ICH Q9): Structured FMEA and Process Auditing
ICH Q9 guidelines provide a systematic process for assessing, controlling, and reviewing quality risks. Quality Risk Management (QRM) has transitioned from a recommendation to a core requirement across international GMP guidelines. In this guide, we review QRM principles and detail how to construct a Failure Mode and Effects Analysis (FMEA) for pharmaceutical systems.
The QRM Lifecycle
A QRM program consists of four main phases: Risk Assessment (identifying and evaluating hazards), Risk Control (implementing actions to mitigate risks), Risk Communication (sharing findings across the organization), and Risk Review (monitoring performance and updating profiles). The process is dynamic, ensuring that risks are continuously evaluated as facilities modify equipment or update procedures.
Constructing an FMEA Assessment
Failure Mode and Effects Analysis (FMEA) is a powerful, quantitative tool used to evaluate potential failures in machinery, software, or manufacturing steps. The risk team assigns scores from 1 to 10 for three attributes:
- Severity (S): How severe is the impact of the failure on product safety or quality? (1 = no impact, 10 = critical failure).
- Occurrence (O): What is the probability that the failure will happen? (1 = rare, 10 = almost certain).
- Detection (D): What is the likelihood that the failure will be detected before reaching the patient? (1 = guaranteed detection, 10 = no detection controls).
The team then calculates the Risk Priority Number (RPN):
RPN = Severity × Occurrence × Detection
Implementing Mitigating Actions
If the RPN exceeds a defined threshold (typically 100), the quality unit must implement mitigating actions. This might include adding automated sensors, rewriting training programs, or scheduling routine calibrations. Once the actions are completed, the RPN is re-calculated. Applying ICH Q9 QRM principles enables pharmaceutical sites to prioritize resources and prevent compliance failures.
Subscribe to our monthly GMP newsletter
Receive Hyderabad pharmaceutical regulatory updates directly to your inbox.
Join Newsletter List